Practical Use of the New American Urological Association Interstitial Cystitis Guidelines
- 605 Downloads
The American Urological Association recently developed guidelines to assist clinicians who evaluate and treat interstitial cystitis/bladder pain syndrome. Knowledge in this area continues to advance, and some of the guideline statements differ from what clinicians may have been previously taught. This review includes the 27 guideline statements, which address both evaluation and treatment. This review lists the guideline statements and, when applicable, comments on their practical implementation and the most recent research. Practical information includes the following: key questions that help in the differential diagnosis, when to perform cystoscopy and urodynamics, how to recognize and treat Hunner lesions, useful practical resources for patients and clinicians, information on elimination diet and stress management, initial selection of oral and intravesical medications, and description of advanced treatment options (limited to dedicated, experienced clinicians).
KeywordsInterstitial cystitis Diagnosis Therapy Painful bladder syndrome Guidelines
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.••Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70. This is the AUA Guideline manuscript, on which this article is based. The document, algorithm, and slide presentation are available on the AUA Web site.PubMedCrossRefGoogle Scholar
- 4.••Logadottir Y, Fall M, Kåbjörn-Gustafsson C, Peeker R. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012; Epub ahead of print. This is the latest update on clinical differences between patients with and without Hunner lesions. Google Scholar
- 5.Koziol JA. Epidemiology of interstitial cystitis. Urol Clin N Am. 1994;21(1):7–20.Google Scholar
- 13.•Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183:1853–8. At first glance, this article appears to show no benefit to amitriptyline, but it is important to note that all patients in this study received education, which was likely to contribute to symptom improvement in the placebo group.PubMedCrossRefGoogle Scholar
- 14.Moldwin RM. The interstitial cystitis survival guide. Oakland: New Harbinger Publications; 2000.Google Scholar
- 16.••Buffington CA. Idiopathic cystitis in domestic cats--beyond the lower urinary tract. J Vet Intern Med. 2011;25:784–96. This article discusses the role of the nervous system in feline IC, including a description of how the feline symptoms improve with environmental changes alone.PubMedCrossRefGoogle Scholar
- 22.••Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103:910–8. After five daily doses, alkalinized lidocaine was more effective than placebo.PubMedCrossRefGoogle Scholar
- 24.••Lv YS, Zhou HL, Mao HP, et al. Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J. 2012; Epub ahead of print. This three-arm trial included alkalinized lidocaine alone, hyaluronic acid alone, or both together. At week 4, all groups had approximately a 30 % response rate. At week 24, response rates were about 68 % for the two hyaluronic acid groups but only about 8 % for alkalinized lidocaine alone. Google Scholar
- 26.Nickel JC, Steele SS, Lekstrom-Himes J, et al. Ascending dose cohort study of LiRIS® (lidocaine-releasing intravesical system) in women with moderate to severe interstitial cystitis [abstract 825]. Presented at the AUA 2012 Annual Meeting, Atlanta, Georgia, May 21, 2012.Google Scholar
- 27.•Quillin R, Hooper G, Erickson D. Intravesical bupivacaine for lidocaine-refractory patients with painful bladder syndrome/interstitial cystitis. Neurourol Urodyn. 2010;29:299. The important clinical message is not to give up if lidocaine fails; some of these patients will respond to bupivacaine.Google Scholar
- 35.••Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner’s ulcer subtype interstitial cystitis. Can J Urol. 2009;16:4536–40. This is the first published description of triamcinolone injection for Hunner lesions.PubMedGoogle Scholar
- 36.Mayer R. Beyond the front lines: what to consider when initial therapy just isn’t enough. ICA Update Spring 2012.Google Scholar
- 37.•Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of three tertiary centers. J Urol. in press, 2012. Cyclosporine A was life-altering in some of the Hunner lesion patients, but adverse events included renal insufficiency and hypertension, and some patients stopped the drug due to adverse events. In contrast, patients without Hunner lesions had a low success rate. Google Scholar
- 39.Hohenfeller M, Linn J, Hampel C, Thuroff JW. Surgical treatment of interstitial cystitis. In: Sant GR, editor. Interstitial cystitis. Philadelphia: Lippincott-Raven; 1997. p. 223–33.Google Scholar
- 41.American Urological Association Education and Research, Inc. Interstitial cystitis/bladder pain syndrome/ IC/BPS clinical guideline. Available at http://www.auanet.org/content/media/IC%20Slide%20Presentation.2011.ppsx. Accessed June 2012.